NNovo Nordisk Read More Novo Nordisk’s Pipeline Successor Outperforms Flagship Weight-Loss Drug2026-03-28 New clinical data shows UBT251 leads to 9.8% weight loss vs. semaglutide’s 4.8%, as Novo Nordisk expands its…